Alkermes (ALKS) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | 122.18% |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | -33.32% |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | 63.07% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -11.73% |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | 243.47% |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | 107.90% |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | 1,034.67% |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 63.59% |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | -3.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.34% |
| Mar 31, 2026 | -267.74% |
| Dec 31, 2025 | -10.68% |
| Sep 30, 2025 | 24.61% |
| Jun 30, 2025 | 2.86% |
| Mar 31, 2025 | 368.12% |
| Dec 31, 2024 | 77.55% |
| Sep 30, 2024 | -18.17% |
| Jun 30, 2024 | -32.30% |
| Mar 31, 2024 | 199.09% |
| Dec 31, 2023 | 10,142.31% |
| Sep 30, 2023 | 15,853.28% |
| Jun 30, 2023 | 9,454.29% |
| Mar 31, 2023 | -198.27% |
| Dec 31, 2022 | -96.62% |
| Sep 30, 2022 | -99.24% |
| Jun 30, 2022 | -106.97% |
| Mar 31, 2022 | 148.02% |
| Dec 31, 2021 | -53.94% |
| Sep 30, 2021 | 37.50% |